Yüksel Ürün, Medical Oncology professor at Ankara University School of Medicine, shared an article by Jedd D. Wolchok, et al. on X:
“20 years ago, metastatic melanoma meant death in a year.
Today?
- 10-yr Overall Survival: 43% (nivo+ipi).
- 10-yr Melanoma-Specific Survival: 52%.
This isn’t improvement. It’s a revolution. Believe in science.”
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.
Authors: Jedd D. Wolchok, et al.
